Rapid Idylla ™ mutational testing: Current and future theranostic applications

Ann Pathol. 2022 Jan 3:S0242-6498(21)00266-2. doi: 10.1016/j.annpat.2021.12.007. Online ahead of print.ABSTRACTMolecular analyses have become mandatory for treatment choices in patients with various advanced cancers. Beside next generation sequencing (NGS) analyzing genes panels, non-NGS targeted analyses about the main biomarkers remain of interest. In this article, we review the data about the fast and fully automated real-time PCR platform Idylla™ (Biocartis, Mechelen, Belgium) permitting the mutational analyses of BRAF, KRAS, NRAS, EGFR and microsatellite instability notably in melanoma, non-small-cell lung cancer and colorectal cancer samples. Future applications as well as the implementation of Idylla™ in the workflow of pathology and/or molecular biology laboratories are also discussed.PMID:34991924 | DOI:10.1016/j.annpat.2021.12.007
Source: Annales de Pathologie - Category: Pathology Authors: Source Type: research